Skandinaviska Enskilda Banken AB publ increased its holdings in shares of Celgene Co. (NASDAQ:CELG) by 144.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 993,229 shares of the biopharmaceutical company’s stock after purchasing an additional 587,500 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned approximately 0.14% of Celgene worth $88,884,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of the stock. Edgewood Management LLC increased its position in Celgene by 16.2% during the second quarter. Edgewood Management LLC now owns 13,924,544 shares of the biopharmaceutical company’s stock worth $1,105,887,000 after buying an additional 1,943,607 shares during the period. FMR LLC increased its holdings in shares of Celgene by 14.8% in the second quarter. FMR LLC now owns 8,160,001 shares of the biopharmaceutical company’s stock valued at $648,067,000 after purchasing an additional 1,051,528 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Celgene by 60.6% in the second quarter. Renaissance Technologies LLC now owns 4,129,438 shares of the biopharmaceutical company’s stock valued at $327,960,000 after purchasing an additional 1,558,600 shares during the period. American Century Companies Inc. increased its holdings in shares of Celgene by 3.3% in the third quarter. American Century Companies Inc. now owns 3,874,067 shares of the biopharmaceutical company’s stock valued at $346,690,000 after purchasing an additional 124,912 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its holdings in shares of Celgene by 11.3% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,648,481 shares of the biopharmaceutical company’s stock valued at $210,342,000 after purchasing an additional 268,597 shares during the period. Hedge funds and other institutional investors own 73.58% of the company’s stock.
A number of research analysts have recently issued reports on CELG shares. BidaskClub lowered Celgene from a “hold” rating to a “sell” rating in a report on Wednesday, October 24th. Zacks Investment Research lowered Celgene from a “buy” rating to a “hold” rating in a report on Wednesday, September 26th. Mizuho set a $117.00 target price on Celgene and gave the company a “buy” rating in a report on Tuesday, October 30th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Celgene in a report on Thursday, October 25th. Finally, Cantor Fitzgerald started coverage on Celgene in a report on Monday, October 1st. They issued an “overweight” rating and a $100.00 target price on the stock. Three analysts have rated the stock with a sell rating, eleven have given a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. Celgene has a consensus rating of “Buy” and a consensus target price of $117.91.
Shares of CELG stock opened at $74.02 on Friday. Celgene Co. has a 1-year low of $70.09 and a 1-year high of $110.81. The firm has a market cap of $52.77 billion, a P/E ratio of 10.82, a price-to-earnings-growth ratio of 0.47 and a beta of 1.53. The company has a current ratio of 2.13, a quick ratio of 1.99 and a debt-to-equity ratio of 4.06.
Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.02 by $0.27. Celgene had a return on equity of 108.76% and a net margin of 19.64%. The firm had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.83 billion. Equities analysts predict that Celgene Co. will post 7.45 EPS for the current fiscal year.
WARNING: “Celgene Co. (CELG) Position Raised by Skandinaviska Enskilda Banken AB publ” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.americanbankingnews.com/2018/11/10/celgene-co-celg-position-raised-by-skandinaviska-enskilda-banken-ab-publ.html.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Recommended Story: Day Trading – Risk Worth the Reward?
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.